Graphene Oxide Nanoparticles and Organoids: A Prospective Advanced Model for Pancreatic Cancer Research

Shaoshan Mai1, Iwona Inkielewicz-Stepniak1

  • 1Department of Pharmaceutical Pathophysiology, Faculty of Pharmacy, Medical University of Gdańsk, 80-210 Gdańsk, Poland.

Insights

This review explores organoids and graphene oxide (GO) for pancreatic cancer research. Combining these technologies offers potential for personalized medicine and improved diagnostics for this aggressive disease.

Area of Science:

  • Biomedical Engineering
  • Cancer Research
  • Materials Science

Background:

  • Pancreatic cancer has a low survival rate due to late diagnosis and limited treatments.
  • Organoid technology and 3D printing offer new avenues for studying complex diseases.
  • Graphene oxide (GO) possesses unique properties beneficial for cancer diagnostics and therapeutics.

Purpose of the Study:

  • To review the generation and application of organoids in pancreatic cancer research.
  • To examine the role of graphene oxide (GO) in cancer diagnostics and therapeutics.
  • To analyze the integration of GO with organoid systems for pancreatic cancer treatment.

Main Methods:

  • Review of organoid generation from various cell sources (tissue, biopsy, stem cells).
  • Exploration of 3D printing advancements in organoid development.
  • Analysis of graphene oxide's properties and its interaction with tumor microenvironments.
  • Assessment of GO-integrated organoid systems for drug delivery and imaging.

Main Results:

  • Organoids provide a platform to study the tumor microenvironment, including non-neoplastic cells and angiogenesis.
  • Graphene oxide demonstrates potential for targeted drug delivery and enhanced imaging in cancer.
  • Integration of GO with organoids shows promise for personalized medicine and drug screening.

Conclusions:

  • Organoid and graphene oxide integration presents a promising strategy for advancing pancreatic cancer research.
  • This approach could lead to improved early detection, targeted therapies, and biomarker discovery.
  • Further research is needed to overcome current limitations and fully realize the potential of this innovative technology.